A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923

A. Hamilton; D. Larsimont; R. Paridaens; M. Drijkoningen; M. van de Vijver; P. Bruning; A. Hanby; S. Houston; I. Treilleux; J. P. Guastalla; A. van Vreckem; R. Sylvester; M. Piccart

doi:https://doi.org/10.3816/CBC.2000.n.020

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923

A. Hamilton, D. Larsimont, R. Paridaens, M. Drijkoningen, M. van de Vijver, P. Bruning, A. Hanby, S. Houston, I. Treilleux, J. P. Guastalla, A. van Vreckem, R. Sylvester, M. Piccart

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

46 Citations (Scopus)

Abstract

This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer

Original language	English
Pages (from-to)	233-40; discussion 241-2
Journal	Clinical Breast Cancer
Volume	1
Issue number	3
DOIs	https://doi.org/10.3816/CBC.2000.n.020
Publication status	Published - 2000

Access to Document

https://doi.org/10.3816/CBC.2000.n.020

Cite this

Hamilton, A., Larsimont, D., Paridaens, R., Drijkoningen, M., van de Vijver, M., Bruning, P., Hanby, A., Houston, S., Treilleux, I., Guastalla, J. P., van Vreckem, A., Sylvester, R., & Piccart, M. (2000). A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clinical Breast Cancer, 1(3), 233-40; discussion 241-2. https://doi.org/10.3816/CBC.2000.n.020

@article{33b01cab80a146948def61c68baf11dd,

title = "A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923",

abstract = "This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer",

author = "A. Hamilton and D. Larsimont and R. Paridaens and M. Drijkoningen and {van de Vijver}, M. and P. Bruning and A. Hanby and S. Houston and I. Treilleux and Guastalla, {J. P.} and {van Vreckem}, A. and R. Sylvester and M. Piccart",

year = "2000",

doi = "https://doi.org/10.3816/CBC.2000.n.020",

language = "English",

volume = "1",

pages = "233--40; discussion 241--2",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier",

number = "3",

}

Hamilton, A, Larsimont, D, Paridaens, R, Drijkoningen, M, van de Vijver, M, Bruning, P, Hanby, A, Houston, S, Treilleux, I, Guastalla, JP, van Vreckem, A, Sylvester, R & Piccart, M 2000, 'A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923', Clinical Breast Cancer, vol. 1, no. 3, pp. 233-40; discussion 241-2. https://doi.org/10.3816/CBC.2000.n.020

A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. / Hamilton, A.; Larsimont, D.; Paridaens, R. et al.
In: Clinical Breast Cancer, Vol. 1, No. 3, 2000, p. 233-40; discussion 241-2.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923

AU - Hamilton, A.

AU - Larsimont, D.

AU - Paridaens, R.

AU - Drijkoningen, M.

AU - van de Vijver, M.

AU - Bruning, P.

AU - Hanby, A.

AU - Houston, S.

AU - Treilleux, I.

AU - Guastalla, J. P.

AU - van Vreckem, A.

AU - Sylvester, R.

AU - Piccart, M.

PY - 2000

Y1 - 2000

N2 - This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer

AB - This study assesses the potential value of the tumor markers p53, HER2, and Bcl-2 in predicting the clinical response to doxorubicin and paclitaxel as single agents in the treatment of metastatic breast cancer. The primary tumors of 114 patients in the European Organization for Research and Treatment of Cancer 10923 trial were assessed by immunohistochemistry using monoclonal antibodies; the results were correlated with clinical response to therapy. HER2 was positive in 24% of patients, p53 was positive in 25% of patients, and Bcl-2 was positive in 49% of patients. There was no correlation between the expression of any of the markers and the clinical response to either agent. Although methodologically limited, this study does not support the use of p53, HER2, or Bcl-2 to assist the selection of anthracycline versus taxane in metastatic breast cancer

U2 - https://doi.org/10.3816/CBC.2000.n.020

DO - https://doi.org/10.3816/CBC.2000.n.020

M3 - Article

C2 - 11899648

SN - 1526-8209

VL - 1

SP - 233-40; discussion 241-2

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 3

ER -

Hamilton A, Larsimont D, Paridaens R, Drijkoningen M, van de Vijver M, Bruning P et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clinical Breast Cancer. 2000;1(3):233-40; discussion 241-2. doi: https://doi.org/10.3816/CBC.2000.n.020